Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $11.86 Average Target Price from Brokerages
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) has been given an average rating of “Hold” by the ten analysts that are currently covering the firm, MarketBeat Ratings reports. Two analysts have rated the stock with a sell rating, four have given a hold rating and four have assigned a buy rating to the company. […]
More Stories
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) Announces January 16th IPO
LogProStyle Inc. (Kabushiki Kaisha LogProstyle) (LGPS) expects to raise $12 million in an IPO on Thursday, January 16th, IPO Scoop...
Top humanitarian official issues ceasefire appeal during visit to Gaza City
The UN Humanitarian Coordinator for the Occupied Palestinian Territory called on Sunday for an end to the war in Gaza...
Comparing AGC (OTCMKTS:ASGLY) & Sonic Healthcare (OTCMKTS:SKHHY)
AGC (OTCMKTS:ASGLY – Get Free Report) and Sonic Healthcare (OTCMKTS:SKHHY – Get Free Report) are both mid-cap industrial products companies,...
Comparing South Bow (SOBO) and Its Rivals
South Bow (NYSE:SOBO – Get Free Report) is one of 21 public companies in the “Pipelines, Except Natural Gas” industry,...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...
Trimedyne (OTCMKTS:TMED) Shares Cross Below 200 Day Moving Average – Here’s What Happened
Shares of Trimedyne, Inc. (OTCMKTS:TMED – Get Free Report) crossed below its two hundred day moving average during trading on...